Proteomics is the study of the proteome and its function. The Proteomics Core at Mayo Clinic's campus in Rochester, Minnesota, provides powerful proteomics tools to study a wide range of biomedical questions, from biomarker discovery, signaling pathway analysis, interactome analysis and drug target analysis to targeted quantitation of proteins in clinical samples and development of diagnostic assays.
Under the leadership of director Akhilesh Pandey, M.D., Ph.D., the scientists at the core not only offer routine services to identify and quantify proteins in regular biological samples, such as gel bands, and cell or tissue lysates but also develop customized proteomics strategies with investigators. To achieve client research goals, the core combines state-of-the-art mass spectrometers with various types of proteomics techniques, ranging from stable isotope labeling by amino acids in cell culture (SILAC) and tandem mass tags (TMT) quantitation to affinity-based enrichment of proteins and their post-translational modifications, such as phosphorylation and ubiquitination, to laser capture microdissection (LCM). The Proteomics Core will also continue to arm investigators with new technology platforms to tackle scientific questions that were unsolvable before.
The Proteomics Core is one of the three core facilities that make up the Medical Genome Facility (MGF). The MGF receives funding from Mayo Clinic's Center for Individualized Medicine and the Research Core Subcommittee. The Proteomics Core receives additional funding from the Mayo Clinic Cancer Center and its National Cancer Institute Cancer Center Support Grant.
The Proteomics Core provides services to all Mayo Clinic faculty and staff engaged in research. Additionally, services are offered to non-Mayo investigators and research collaborators. For more information, please contact the core.